Dr. Sarawut KumphuneAssociate Professor
Biomedical Engineering Institute, Faculty of Engineering, Chiang Mai University, Thailand
Speech Title: The cardioprotective potential of secretory leukocyte protease inhibitor (SLPI): new therapeutic candidate for Ischemic Heart Disease
Abstract: Despite advances in both knowledge and technology, Ischemic Heart Disease (IHD) remains the most common cause of death world-wide and is predicted to remain a serious cause of death in the future. One of the major causes of cardiac cell death during myocardial ischemia is the over secretion of protease enzymes surrounding the ischemic tissue. Therefore, inhibition of protease activity can, therefore, be considered as a powerful strategy for attenuation of ischaemia/reperfusion (I/R) injury, as well as further detrimental progression and, therefore, be considered as an alternative therapeutic strategy to save patients’ life from myocardial I/R injury. The secretory leukocyte protease inhibitor (SLPI) is an 11.7 kDa non-glycosylated cationic protein, which has been known to inhibit several inflammatory proteases with several pharmaceutical effects. Our group showed several strategies, by means of gene overexpression and treatment of the recombinant proteins, in several cardiovascular related cell types such as cardiomyocytes, cardiac fibroblast, and vascular endothelial cells. The overexpression, as well as treatment with recombinant human(rh)-SLPI showed cardioprotective effect against in vitro I/R injury, ex vivo global ischaemia, and in vivo left anterior descending (LAD) coronary artery occlusion. The results also demonstrated that rhSLPI could potentially reduce reactive oxygen species, inflammation, apoptotic regulatory protein expression, and enhanced cell survival kinases. In conclusion, our group is the first and only group to study the role of SLPI in myocardial I/R injury and revealed its cardioprotective activity, which highlight the pharmaceutical potential of SLPI as a novel therapeutic candidate for IHD.
Keywords: ischaemic heart disease; ischaemia/reperfusion injury; secretory leukocyte protease inhibitor (SLPI); cardioprotection
Biography: Dr. Sarawut Kumphune is an Associate Professor, he graduated the first degree in Medical Technology, and master’s degree in Biochemistry from Mahidol University, Thailand. Later in 2009, he was awarded PhD in Medicine – Cardiovascular Research from King’s College London, University of London. He formerly worked at Naresuan University, being a head of Biomedical Research Unit in Cardiovascular Science, which nowadays reformed as The Integrative Biomedical Research Unit in 2020 before leave Naresuan University to work at Molecular Biology and Biochemistry Unit, Biomedical Engineering Institute, Chiang Mai University.
His researches of interests are Cell and Molecular Biology, Molecular Cardiology, Cardiovascular Sciences, Biochemistry, Pharmaceutical Sciences, Clinical Biochemistry, Biomarker, Drug and Gene delivery. Until now, he has received several research grants from National and International grant agencies, several international research publications as well as international collaboration.